Literature DB >> 17941181

Release, purification, and characterization of platelet-activating factor (PAF).

V Tencé1, J Polonsky, J P Le Couedic, M J Benveniste.   

Abstract

Platelet-activating factor (PAF) is a phospholipid mediator, released by basophils, macrophages and neutrophils under immunological and non immunological stimuli. It aggregates platelets and liberates their vasoactive contents. We studied the "spontaneous" release of PAF from hog blood leukocytes : optimal conditions were 22 degrees C, pH 9.5 in BSA and Ca2+-containing Tyrode's. This release was inhibited by the Ca2+-chelating agent, EDTA, and by the phospholipase A2 inhibitor, bromophenacyl bromide. Disruption of the cells did not yield PAF, indicating that it is not a "preformed" mediator. A preparative procedure for the extraction and purification of bulk quantities of PAF was developed. Purification was performed by silicic acid columns followed by high pressure liquid chromatography. The active fraction was eluted between sphingomyelin and lysophosphatidylcholine. The PAF purest fractions were still contaminated with these phospholipids as shown by thin layer chromatography and chemical ionization mass spectrometry. PAF activity was not affected by treatment with diazomethane, acetylation or hydrogenation. Our results combined with those obtained from our previous studies of the PAF structure using specific phospholipases indicate that PAF is a glycero-phospholipid devoid of ester function at position 1. This allowed us to establish precise criteria to distinguish PAF from other aggregating agents.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 17941181     DOI: 10.1016/s0300-9084(80)80399-3

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  20 in total

1. 

Authors:  R Rochels
Journal:  Doc Ophthalmol       Date:  1984-05       Impact factor: 2.379

2.  Intestinal epithelial cells contribute to the enhanced generation of platelet activating factor in ulcerative colitis.

Authors:  L Ferraris; F Karmeli; R Eliakim; J Klein; C Fiocchi; D Rachmilewitz
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

3.  Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues.

Authors:  N P Stimler; J T O'Flaherty
Journal:  Am J Pathol       Date:  1983-10       Impact factor: 4.307

Review 4.  Biology and biochemistry of platelet-activating factor.

Authors:  J T O'Flaherty; R L Wykle
Journal:  Clin Rev Allergy       Date:  1983-09

Review 5.  Cytokines and other mediators in rheumatoid arthritis.

Authors:  J M Dayer; S Demczuk
Journal:  Springer Semin Immunopathol       Date:  1984

6.  Biosynthesis of paf-acether. Paf-acether but not leukotriene C4 production is impaired in cultured macrophages.

Authors:  A Dulioust; E Vivier; N Meslier; R Roubin; I Haye-Legrand; J Benveniste
Journal:  Biochem J       Date:  1989-10-01       Impact factor: 3.857

7.  Presence of paf-acether in rheumatic diseases.

Authors:  P Hilliquin; C J Menkes; S Laoussadi; J Benveniste; B Arnoux
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

8.  Gastric secretion of platelet activating factor and precursors in healthy humans: effect of pentagastrin.

Authors:  I Sobhani; Y Denizot; S Hochlaf; D Rigaud; J Vatier; J Benveniste; M J Lewin; M Mignon
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

9.  Release of platelet-activating factor (PAF-acether) and 2-lyso PAF-acether from three cell types.

Authors:  J Benveniste; R Roubin; M Chignard; E Jouvin-Marche; J P Le Couedic
Journal:  Agents Actions       Date:  1982-12

10.  Human platelets release a paf-acether: acetylhydrolase similar to that in plasma.

Authors:  R Korth; J Bidault; R Palmantier; J Benveniste; E Ninio
Journal:  Lipids       Date:  1993-03       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.